ALUMIS INC. - COMMON STOCK

9.4600

22-November-24 16:44:58

15 minutes delayed

Stocks

+0.0200

+0.21%

Today's range

9.0900 - 9.7200

ISIN

N/A

Source

NASDAQ

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

14 Nov 2024 16:05:00 By Nasdaq GlobeNewswire
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

13 Nov 2024 16:05:48 By Nasdaq GlobeNewswire
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

04 Nov 2024 08:00:00 By Nasdaq GlobeNewswire
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

27 Sep 2024 09:00:00 By Nasdaq GlobeNewswire
Alumis to Participate in Upcoming September Investor Conferences

03 Sep 2024 16:29:30 By Nasdaq GlobeNewswire
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

13 Aug 2024 16:05:27 By Nasdaq GlobeNewswire
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

29 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

<<
<
1
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.